PagerDuty (PD) Q4 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2241560/pagerduty-pd-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2241560
Mar 15, 2024 - PagerDuty's (PD) fourth-quarter fiscal 2024 results benefit from an expanding customer base.
0
PagerDuty (PD) Q4 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2241032/pagerduty-pd-q4-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2241032
Mar 14, 2024 - PagerDuty (PD) delivered earnings and revenue surprises of 13.33% and 0.56%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
0
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
https://seekingalpha.com/article/4662621-pds-biotechnology-promising-phase-2-cash-issues-worth-risk?source=feed_all_articles
Jan 12, 2024 - PDS Biotech, a clinical-stage company specializing in immunotherapy for cancer, with a focus on virus-driven tumors and promising clinical data. Read more here.
0